HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (10) Citing Articles via Google Scholar Google Scholar Articles by Vila-Córcoles, A. Articles by Gómez, A. Search for Related Content PubMed PubMed Citation Articles by Vila-Córcoles, A. Articles by Gómez, A.

Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects

¹ EVAN-65 Group of Primary Care Service Tarragona-Valls, Institut Catalá de la Salut, Tarragona, and ² Dept of Statistic and Research of Jordi Gol i Gurina, Barcelona, Spain.

CORRESPONDENCE: A. Vila-Corcoles, Institut Català de la Salut, Prat de la Riba 39, Tarragona 43001, Spain. Fax: 34 977226411. E-mail: avila.tarte.ics{at}gencat.net

Keywords: Effectiveness, elderly, mortality, pneumococcal vaccine, pneumonia

Received: March 15, 2005
Accepted August 14, 2005

The present study assessed the effectiveness of the 23-valent pneumococcal polysaccharide vaccine to prevent pneumonia and death in older adults in a first-time report between January and December 2002.

A prospective cohort study was conducted including all individuals 65 yrs of age assigned to one of eight primary care centres in Tarragona, Spain (n = 11,241). The primary outcomes were community-acquired pneumonia (hospitalised or outpatient) and death from pneumonia. All pneumonias were validated by checking clinical records. The association between the pneumococcal vaccination and the risk of each outcome was evaluated by means of multivariate Cox proportional-hazard models, adjusted by age, sex, influenza vaccination status, comorbidity and immunological status.

Pneumococcal vaccination did not alter the risk of hospitalisation from pneumonia (hazard ratio (HR): 0.80; 95% confidence interval (CI): 0.50–1.28) or overall pneumonia (HR: 0.86; 95% CI: 0.56–1.31), but the vaccine was associated with considerable reductions of death risk from pneumonia (HR: 0.28; 95% CI: 0.09–0.83).

In conclusion, these results suggest that pneumococcal polysaccharide vaccine may not be effective in reducing the incidence of pneumonia, but may be able to diminish the severity of the infection. These findings support the effectiveness of the pneumococcal polysaccharide vaccine to prevent mortality caused by pneumonia in older adults, providing a new argument to recommend systematic vaccination in the elderly.

This article has been cited by other articles:

				C. Garcia-Vidal, N. Fernandez-Sabe, J. Carratala, V. Diaz, R. Verdaguer, J. Dorca, F. Manresa, and F. Gudiol Early mortality in patients with community-acquired pneumonia: causes and risk factors Eur. Respir. J., September 1, 2008; 32(3): 733 - 739. [Abstract] [Full Text] [PDF]

				J. Johnstone, T. J. Marrie, D. T. Eurich, and S. R. Majumdar Effect of Pneumococcal Vaccination in Hospitalized Adults With Community-Acquired Pneumonia Arch Intern Med, October 8, 2007; 167(18): 1938 - 1943. [Abstract] [Full Text] [PDF]

				K. A. Spaude, E. Abrutyn, C. Kirchner, A. Kim, J. Daley, and D. N. Fisman Influenza Vaccination and Risk of Mortality Among Adults Hospitalized With Community-Acquired Pneumonia Arch Intern Med, January 8, 2007; 167(1): 53 - 59. [Abstract] [Full Text] [PDF]